Introduction
High concentrations of triglycerides and triglyceride-rich lipoproteins are associated with high risk of atherosclerotic cardiovascular disease (ASCVD). [1] [2] [3] [4] [5] Genetic studies have further corroborated the observational findings and strongly indicated that this is a causal association. [4] [5] [6] [7] Importantly, it is now also evident based on both genetic studies and randomized clinical trials (RCTs) that the association between triglycerides and ASCVD is not due to the inverse association between triglycerides and high-density lipoprotein (HDL) cholesterol, as high HDL cholesterol due to genetic variation or pharmacological treatment does not protect against ASCVD. 4, 5, [8] [9] [10] Despite the strong evidence linking triglycerides and triglyceride-rich lipoproteins to risk of ASCVD, no large RCTs evaluating the effect of triglyceride-lowering for primary prevention of ASCVD in individuals with mild-tomoderate hypertriglyceridaemia have been conducted. 11, 12 More than 80% of ASCVD events occur in individuals who are not eligible for prophylactic statin therapy according to the current guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 13 Some of these events may occur in individuals with hypertriglyceridaemia, and it is unknown whether there is an unmet need for primary prevention in such individuals. We hypothesized that it is possible to identify individuals at high risk of ASCVD who are not definite statin eligible according to the 2016 ESC/EAS guidelines, 11, 12 based on high concentrations of plasma triglycerides. If this is the case, it would indicate an unmet clinical need in such individuals, calling for expansion of guidelines on statin eligibility, and these individuals could be a target group for future placebo-controlled RCTs. To test this hypothesis, we included 58 547 individuals aged 40-65 from the Copenhagen General Population Study (CGPS) who were free of ASCVD, diabetes, and statin use, and divided them according to statin eligibility and concentrations of triglycerides, and determined the absolute risk of ASCVD in these subgroups.
Methods Population
White individuals of Danish descent according to the Danish Civil Registration System, that is, the person and both parents were born in Denmark and were Danish citizens, were included from the CGPS between 2003 and 2015; individuals aged 20-100þ were invited randomly from the general population of Copenhagen using information from the Danish Civil Registration System. 14 The overall participation rate was 43%.
At the baseline examination participants answered a questionnaire regarding health, lifestyle etc., which was reviewed with an investigator on the day of attendance, and underwent a physical examination. In addition, blood was drawn for biochemical measurements. Written informed consent was obtained from all. Studies were conducted in accordance with the Declaration of Helsinki and approved by local institutional reviews boards and a Danish ethics committee (H-KF-01-144/01).
For the present study, we initially excluded individuals with missing information on variables used for risk classification (see Supplementary material online, Figure S1 ). Subsequently, individuals aged below 40 years or above 65 years were excluded as the European SCORE predicts risk of fatal ASCVD in non-diabetic individuals between 40 and 65 years of age. 11, 12, 15 Lastly, we excluded individuals with ASCVD and/or diabetes and/or individuals who were statin users at baseline to obtain a nondiabetic population in which to evaluate a possible unmet clinical need for primary prevention based on high concentrations of triglycerides. Statin users free of ASCVD and diabetes were not included in the primary analyses, but their statin eligibility was determined and risk estimates for these two groups included for comparison.
Variables
Variables used to ascertain ASCVD risk and statin eligibility according to the 2016 ESC/EAS guidelines included age, sex, smoking status, systolic and diastolic blood pressure, total cholesterol, low-density lipoprotein (LDL) cholesterol, HDL cholesterol, and chronic kidney disease. Blood samples were non-fasting. 16 A full description of variables is provided in the Supplementary material online, Appendix.
Endpoints
All events were ascertained using the national Danish Patient Registry which cover all contacts (in-and outpatient) to Danish hospitals, and the national Danish Register of Causes of Death until end of follow-up March 2017. Included endpoints were myocardial infarction (MI) and the composite endpoint major adverse cardiovascular event (MACE) which included cardiovascular death, non-fatal MI, unstable angina pectoris, and stroke. A full description of endpoints is provided in the Supplementary material online, Appendix.
Criteria for statin eligibility
The criteria used to assign individuals as definite statin eligible for primary prevention were based on class I and IIa recommendations from the 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias, 11 which are similar to those stated in the 2016 ESC/EAS Guidelines on ASCVD Prevention in Clinical Practice. 12 These guidelines combine risk categorization with LDL cholesterol levels. Risk categorization was done based on individual risk factors and the SCORE risk equations as indicated in Table 1 . Individuals with very high risk and LDL cholesterol > _1.8 mmol/L (70 mg/dL) or with high risk and LDL cholesterol > _2.6 mmol/L (100 mg/dL) were defined as definite statin eligible. As Denmark is currently classified as a low risk country, the SCORE lowrisk equations were used. As incorporation of HDL cholesterol into the SCORE equations has been shown to worsen risk classification in the present cohort, 17 the original SCORE risk equations without HDL cholesterol were used. Sensitivity analyses using the SCORE risk equations incorporating HDL cholesterol were also conducted. Regarding hypertriglyceridaemia in the 2016 ESC/EAS guidelines, there are no definite recommendations on initiation of lipid-lowering therapy based on high concentrations of triglycerides.
For comparison, individuals were also assigned to definite statin eligibility based on the 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (ACC/AHA guidelines) 18 and the 2016 US Preventive Services Task Force Recommendations on Statin Use for the Primary Prevention of Cardiovascular Disease in Adults (USPSTF recommendations). 19 The criteria used to determine statin eligibility according the ACC/AHA guidelines and the USPSTF recommendations are shown in Supplementary material online, 
Statistical analyses
Statistical analyses were performed using Stata 13.1 and P-values are two-sided. Baseline characteristics are given as median (interquartile range) for continuous variables and as number (per cent) for categorical variables. The distribution of triglyceride concentrations is shown as a kernel density plot. For the present study, the main outcome measures were absolute risks to best provide estimates to guide identification and enrolment for possible RCTs. Absolute risks were given as incidence rates per 1000 person-years and estimated 10-year risks in per cent. Incidence rates and 95% confidence intervals (CIs) were calculated based on the Poisson distribution. Age and sex adjusted incidence rates were predicted rates following Poisson regression including age and sex as covariates. The aim of the present study was not to provide evidence for a causal relationship between triglycerides and risk of MI and MACE; therefore, only crude and age and sex adjusted estimates were provided, as opposed to multifactorially adjusted estimates. To allow for variable follow-up time, absolute estimated 10-year risks of MI and MACE were estimated nonparametrically using the cumulative incidence function, 20 with death (excluding cardiovascular deaths for the MACE endpoint) and emigration as competing events. For sensitivity analyses a cutoff of 5 years was also used. Cumulative incidence curves were estimated with death (excluding cardiovascular deaths for the MACE endpoint) and emigration as competing events, and age as the underlying timescale. Subhazard ratios and corresponding P-values were obtained from Fine and Gray competing risk regression.
In the initial analyses individuals who were not definite statin eligible were subdivided into six groups based on their triglyceride concentrations with clinically relevant 1 mmol/L (88 mg/dL) cutpoints, as done previously. 1, 3 Based on the initial analyses, individuals who were not definite statin eligible were also divided into two larger groups with triglycerides below or > _3.0 mmol/L (264 mg/dL).
Results
A total of 58 547 individuals aged 40-65 at baseline were included and followed for a median of 8 years (range 0-13). During 456 057
person-years of follow-up, 1770 individuals experienced a MACE and 734 experienced a MI, resulting in overall incidence rates of 3.9 [95% confidence interval (95% CI) 3.7-4.1] and 1.6 (1.5-1.7) per 1000 person-years, respectively. Baseline characteristics for individuals according to statin eligibility and plasma triglycerides, are shown in Table 2 . Baseline characteristics by statin eligibility alone are shown in Supplementary material online, Table S2 .
According to the criteria shown in Table 1 from the 2016 EAS/ESC guidelines, 8092 individuals (14%) were definite statin eligible. The distribution of triglycerides in individuals who were not definite statin eligible is shown in Figure 1 ; 8% of these individuals had triglycerides above 3 mmol/L (264 mg/dL), corresponding to 7% of the total population. The 2016 ESC/EAS guidelines indicate that one could consider pharmacologically treating individuals with very high risk and triglycerides above 2.3 mmol/L (202 mg/dL). In our study, that would apply to only 209 individuals (0.4%) not already definite statin eligible by the LDL cholesterol criteria.
Triglycerides in 1.0 mmol/L (88 mg/dL) cutpoints and risk of major adverse cardiovascular event and myocardial infarction
The incidence rates of MACE and MI increased with increasing concentrations of triglycerides ( Figure 2) . Individuals who were not definite statin eligible and had triglycerides <1.0 mmol/L (88 mg/dL) had the lowest incidence rates of 2.2 (95% CI 1.9-2.5) and 0.6 (0.5-0.8) per 1000 person-years for MACE and MI. Individuals with triglycerides of 4.0-4.99 mmol/L (352-439 mg/dL) had the corresponding highest incidence rates of 7.9 (6.0-10.3) and 4.3 (3.0-6.2), which were similar to the rates for definite statin eligible individuals of 8.2 (7.5-8.9) for MACE and 3.6 (3.2-4.1) for MI. Age and sex adjustment generally attenuated the incidence rates for MACE and MI more in definite statin eligible individuals, as compared to individuals who were not definite statin eligible. showed that in individuals with triglycerides > _3 mmol/L (264 mg/dL) the risks of MACE and MI were similar to the risks in definite statin eligible individuals (P = 0.75 and P = 0.42), and higher than in those with triglycerides <3.0 mmol/L (264 mg/dL) (P < 0.0001 for both endpoints) (Figure 3) .
The cumulative incidences of MACE at age 70 were 8.1% (95% CI 7.3-8.9%) and 14.6% (12.6-16.8%) in individuals who were not statin eligible with triglycerides below or at or above 3.0 mmol/L (264 mg/dL), and 16.5% (14.0-19.3%) in those who were definite statin eligible (Figure 3) . Corresponding cumulative incidences of MI were 3.0% (2.7-3.3%), 7.8% (6.4-9.5%), and 7.1% (5.9-8.4%).
The crude incidence rates for MACE were 2.9 (95% CI 2.7-3.1) and 6.0 (5.2-6.9) per 1000 person-years for individuals who were not definite statin eligible and with triglycerides below and at or above 3.0 mmol/L (264 mg/dL), while it was 8.2 (7.5-8.9) in definite statin eligible individuals ( Figure 4) ; the median age in these three ............................................................................................................................................................................................................ ..... Unmet need for primary prevention in individuals with hypertriglyceridaemia groups were 51, 51, and 60 years, respectively. For comparison, statin users at baseline had crude incidence rates for MACE of 5.2 (4.0-6.9) and 7.2 (5.6-9.0) per 1000 person-years for those who were not definite statin eligible and for those who were eligible. For the endpoint MI, the corresponding crude incidence rates were 1.1 (1.0-1.2), 3.2 (2.6-3.8), 3.6 (3.2-4.1), 3.0 (2.1-4.3), and 3.1 (2.1-4.4) per 1000 person-years, respectively. Similarly, the estimated 10-year risks of MACE and MI were 2.8% (2.6-3.0%) and 1.0% (0.9-1.1%) for individuals who were not definite statin eligible and with triglycerides <3.0 mmol/L (264 mg/dL), 5.7% (4.9-6.6%), and 3.0% (2.4-3.7%) for individuals who were not definite statin eligible and with triglycerides > _3.0 mmol/L (264 mg/dL), 7.6% (6.9-8.3%), and 3.3% (2.8-3.7%) for definite statin eligible individuals, 5.5% (3.9-7.4%) and 3.3% (2.1-5.0%) for statin users who were not definite statin eligible, and 7.1% (5.5-9.1%) and 3.3% (2.2-4.8%) for statin users who were definite statin eligible (Figure 4) . In sensitivity analyses looking at estimated 5 years of risks as opposed to estimated 10 years of risks (compare Supplementary material online, Figure S2 with Figure 4 ) and in analyses using the SCORE risk equations incorporating HDL cholesterol as opposed to the original SCORE risk equations (compare Supplementary material online, Figure S3 with Figure 4 ), results were similar. Furthermore, results were similar when excluding individuals who were not definite statin eligible and had triglycerides >10 mmol/L (880 mg/dL) (n = 26), as such individuals might be treatment candidates due to risk of pancreatitis as indicated in the ESC/EAS guidelines (compare Supplementary material online, Figure S4 with Figure 4) .
Comparison with the ACC/AHA guidelines and the USPSTF recommendations
Among the 58 547 individuals aged 40-65 studied and according to the criteria shown in Supplementary material online, Table S1 from the 2013 ACC/AHA guidelines and the 2016 US Preventive Services Task Force recommendations, 15 986 (27%) and 11 560 (20%) of individuals were definite statin eligible ( Figure 5) . Of the total population, 4% and 5% were not definite statin eligible and had triglycerides above 3 mmol/L (264 mg/dL) for the ACC/AHA guidelines and the USPSTF recommendations. For the ACC/AHA guidelines the estimated 10 years of risks of MACE and MI were 2.3% (2.1-2.4%) and 0.8% (0.7-0.9%) for individuals who were not definite statin eligible and with triglycerides <3.0 mmol/L (264 mg/dL), 4.0% (3.1-5.1%), and 1.9% (1.3-2.6%) for individuals who were not definite statin eligible and with triglycerides > _3.0 mmol/L (264 mg/dL), and 7.3% (6.8-7.8%) and 3.2% (2.9-3.5%) for definite statin eligible individuals ( Figure 5) . Corresponding estimates for the USPSTF recommendations were 2.5% (2.4-2.7%) and 0.9% (0.8-1.0%), 4.3% (3.5-5.2%) and 1.8% (1.3-2.5%), 8.0 (7.5-8.7%) and 3.7% (3.3-4.1%), respectively.
Discussion
This study showed that high concentrations of triglycerides were associated with high absolute risk of ASCVD in individuals who are not definite statin eligible according to the 2016 ESC/EAS guidelines. Specifically, 7% of the general population in our study who were not definite statin eligible and had triglycerides > _3.0 mmol/L (264 mg/dL) were at high risk of ASCVD (Take home figure), indicating that there is an unmet clinical need among ASCVD-free, non-diabetic individuals with hypertriglyceridaemia.
Currently, evidence exists for the importance of triglycerides and triglyceride-rich lipoproteins as causal risk factors for atherosclerotic ASCVD from mechanistic (preclinical), observational, and genetic studies. 5 In the present study, we also observed stepwise increasing risk of ASCVD with increasing triglycerides. Indeed, individuals with triglycerides > _3.0 mmol/L had risk of ASCVD comparable to the risk amongst those who were definite statin eligible, even though their median age was close to 10 years lower and age is a strong driver of ASCVD risk. 21 However, evidence from large RCTs investigating the effect of triglyceride-lowering on risk of ASCVD in individuals with elevated triglycerides is lacking. Results from trials with fibrates, which are capable of lowering triglyceride concentrations, have been mixed leading to the misconception that pharmacological lowering of triglycerides in individuals with elevated triglycerides is not beneficial. 4 However, these trials did not enrol participants based on high triglycerides, and subgroup analyses from these trials showed that lowering of triglycerides reduced the risk of ASCVD most in individuals with triglycerides > _2.0 mmol/L (176 mg/dL) at baseline. 22 Three phase three RCTs evaluating the effect of triglyceridelowering on ASCVD risk in individuals already on a statin are currently ongoing. 5 The treated to lower their risk would be to expand current guidelines on initiation of statin therapy. This is illustrated in this study by comparing the restrictive European guidelines with the more liberal American guidelines. Ways to expand current statin guidelines to include these individuals could be by lowering the predicted risk thresholds used or by simply incorporating thresholds for triglycerides, remnant cholesterol or non-HDL cholesterol in addition to LDL cholesterol. The treatment of individuals with hypertriglyceridaemia in addition to statin therapy would also entail lifestyle interventions as proposed in the different guidelines, as it is evident that the presence of overweight, obesity, and metabolic syndrome is high in individuals with hypertriglyceridaemia.
The findings from the present study indicate that there is a need for placebo-controlled RCTs in individuals with high triglycerides to evaluate the effect of statins or other triglyceride-lowering compounds on the risk of ASCVD. Most prudent would be a primary prevention trial evaluating the effect of a potent statin on ASCVD risk against placebo, or a two by two design with statins and another triglyceride-lowering agent in individuals with elevated triglycerides. 5 This could be done in individuals who are not definite statin eligible according to the current European guidelines, as it would not appear to be unethical to randomize these individuals to placebo in order to estimate the actual effect of the compounds in individuals with high triglycerides. However, as age is the most important driver of risk Figure 3 Cumulative incidence of MACE and myocardial infarction according to statin eligibility and triglycerides at/above or below 3 mmol/L (264 mg/dL). Based on 58 547 individuals from the Copenhagen General Population Study. Cumulative incidence curves were estimated with death (excluding cardiovascular deaths for the MACE endpoint) and emigration as competing events, and with age as the underlying timescale. Subhazard ratios were from Fine and Gray competing risk regression. CI, confidence interval; MACE, major adverse cardiovascular event.
. and subsequent statin eligibility in the guidelines, some of these individuals would over the course of a multiyear RCT revert from being statin non-eligible to being eligible due to advancing age alone, which would affect the power of the study. Despite this, the reality is that even many individuals who are statin eligible are not treated according to current European guidelines. 25, 26 Therefore, future trials could entail randomizing individuals with high triglycerides to either active compound or usual care as judged by the responsible physician, this way better mimicking real-world scenarios and not those in more selective RCTs. The present study provides the basis for identification and recruitment for future RCTs on this matter.
Limitations
Limitations of the present study include lack of information on possible initiation of lipid-lowering therapy following the baseline examination. Selective prescription to individuals at high-risk or with extreme triglyceride or cholesterol concentrations might have affected the observed risk estimates. However, in general initiation of treatment for ASCVD risk factors and adherence to European guidelines on primary prevention is limited in Europe, including in Denmark. 25, 26 Another limitation include the fact that the present study only included white individuals and our results may not necessarily be transferable to other ethnicities, although we are not aware of any Based on 58 547 individuals from the Copenhagen General Population Study. Crude and age and sex adjusted incidence rates with 95% confidence intervals are from Poisson regression. Estimated 10-year risks in per cent were estimated using the cumulative incidence function. Error bars indicate 95% confidence intervals. MACE, major adverse cardiovascular event.
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evidence indicating this. Lastly, not all individuals were followed a full 10 years. This is due to the fact that the present study is based on a contemporary population-based study, which is also one of the strengths, as the overall risk of ASCVD and the use of preventive medicine has changed in most western countries over the last decades. Additional strengths include the large number of consecutively included individuals with complete follow-up due to the Danish health registries. 

Conclusion
In conclusion, high concentrations of triglycerides identify individuals at high risk of ASCVD amongst those that are not definite eligible for statin treatment according to the 2016 ESC/EAS guidelines. This point towards an unmet need for primary prevention, calling for expansion of guidelines on statin eligibility and the need for future placebo-controlled RCTs in individuals with hypertriglyceridaemia.
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